Blood lipids and the incidence of atrial fibrillation: The multi-ethnic study of atherosclerosis and the framingham heart study

Journal of the American Heart Association

Volumn 3, Issue 5, 2014, Pages

  Alonso, Alvaro ^a   Yin, Xiaoyan ^c,d   Roetker, Nicholas S ^a   Magnani, Jared W ^b,d   Kronmal, Richard A ^e   Ellinor, Patrick T ^f   Chen, Lin Y ^g   Lubitz, Steven A ^f   McClelland, Robyn L ^e   McManus, David D ^d,h   Soliman, Elsayed Z ⁱ   Huxley, Rachel R ^j   Nazarian, Saman ^k,l   Szklo, Moyses ^l   Heckbert, Susan R ^e   Benjamin, Emelia J ^b,d,m  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Section of Cardiovascular Medicine   (United States)

^c BOSTON UNIVERSITY   (United States)

^d FRAMINGHAM HEART STUDY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ WAKE FOREST SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^m BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

Atrial fibrillation; Cholesterol; Epidemiology; Lipids; Risk factors

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; AGE DISTRIBUTION; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BLOOD; COMORBIDITY; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; ELECTROCARDIOGRAPHY; ETHNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; SEX RATIO; SURVIVAL RATE;

AGE DISTRIBUTION; AGED; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; COMORBIDITY; CONFIDENCE INTERVALS; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; SURVIVAL RATE; TRIGLYCERIDES;

EID: 84939460850     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001211     Document Type: Article

References (38)

1. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
2. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA. 1999;282:2340-2346.
3. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Rooij FJ, Lip GY, Witteman JC. Subclinical atherosclerosis and risk of atrial fibrillation: the Rotterdam Study. Arch Intern Med. 2007;167:382-387.
4. Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M. Association between lipid profile and risk of atrial fibrillation. Circ J. 2011;75:2767-2774.
5. Lopez FL, Agarwal SK, MacLehose RF, Soliman EZ, Sharrett AR, Huxley RR, Konety S, Ballantyne CM, Alonso A. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities Study. Circ Arrhythm Electrophysiol. 2012;5:155-162.
6. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg C, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96:2455-2461.
7. Iguchi Y, Kimura K, Shibazaki K, Aoki J, Kobayashi K, Sakai K, Sakamoto Y. Annual incidence of atrial fibrillation and related factors in adults. Am J Cardiol. 2010;106:1129-1133.
8. Mora S, Akinkuolie AO, Sandhu RK, Conen D, Albert CM. Paradoxical association of lipoprotein measures with incident atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7:612-619.
9. Bild DE, Bluemke DA, Burke GL, Detrano R, Diez Roux AV, Folsom AR, Greenland P, Jacobs DR Jr, Kronmal R, Liu K, Nelson JC, O'Leary D, Saad MF, Shea S, Szklo M, Tracy RP. Multi-Ethnic Study of Atherosclerosis: objectives and design. Am J Epidemiol. 2002;156:871-881.
10. Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975;4:518-525.
11. Holvoet P, Jenny NS, Schreiner PJ, Tracy RP, Jacobs DR. The relationship between oxidized LDL and other cardiovascular risk factors and subclinical CVD in different ethnic groups: the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007;194:245-252.
12. Ingelsson E, Massaro JM, Sutherland P, Jacques PF, Levy D, D'Agostino RB, Vasan RS, Robins SJ. Contemporary trends in dyslipidemia in the Framingham Heart Study. Arch Intern Med. 2009;169:279-286.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
14. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271:840-844.
15. Irwin ML, Mayer-Davis EJ, Addy CL, Pate RR, Durstine JL, Stolarczyk LM, Ainsworth BE. Moderate-intensity physical activity and fasting insulin levels in women: the Cross-Cultural Activity Participation Study. Diabetes Care. 2000;23:449-454.
16. Lutsey PL, Jacobs DR Jr, Kori S, Mayer-Davis EJ, Shea S, Steffen LM, Szklo M, Tracey R. Whole grain intake and its cross-sectional association with obesity, insulin resistance, inflammation, diabetes and subclinical CVD: the MESA Study. Br J Nutr. 2007;98:397-405.
17. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639.
18. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
19. Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101-129.
20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
21. McClelland RL, Kronmal RA, Haessler J, Blumenthal RS, Godd DC Jr. Estimation of risk factor associations when the response is influenced by medication use: an imputation approach. Stat Med. 2008;27:5039-5053.
22. White IR, Royston P. Imputing missing covariate values for the Cox model. Stat Med. 2009;28:1982-1998.
23. Haywood LJ, Ford CE, Crow RS, Davis BR, Massie BM, Einhorn PT, Williard A; for the ALLHAT Collaborative Research Group. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009;54:2023-2031.
24. Sanchez OA, Duprez DA, Bahrami H, Daniels LB, Folsom AR, Lima JA, Maisel A, Peralta CA, Jacobs DR Jr. The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: the Multi-Ethnic Study of Atherosclerosis. Metabolism. 2014;63:475-483.
25. Patton KK, Heckbert SR, Alonso A, Bahrami H, Lima JA, Burke G, Kronmal RA. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex, and ethnicity. Heart. 2013;99:1832-1836.
26. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, Tofler GH, Selhub J, Jacques PF, Wolf PA, Magnani JW, Ellinor PT, Wang TJ, Levy D, Vasan RS, Benjamin EJ. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. 2010;121:200-207.
27. Sinner MF, Stepas KA, Moser CB, Krijthe BP, Aspelund T, Sotoodehnia N, Fontes JD, Janssens ACJW, Kronmal RA, Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA, Schnabel RB, Vasan RS, Wang TJ, Agarwal SK, McManus DD, Franco OH, Yin X, Larson MG, Burke GL, Launer LJ, Hofman A, Levy D, Gottdiener JS, Kaab S, Couper D, Harris TB, Astor BC, Ballantyne CM, Hoogeveen RC, Arai AE, Soliman EZ, Ellinor PT, Stricker BHC, Gudnason V, Heckbert SR, Pencina MJ, Benjamin EJ, Alonso A. B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies. Europace. 2014;16:1426-1433.
28. Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D. Relations of lipid concentrations to heart failure incidence: the Framingham Heart Study. Circulation. 2009;120:2345-2351.
29. Alonso A, Krijthe BP, Aspelund T, Stepas KA, Pencina MJ, Moser CB, Sinner MF, Sotoodehnia N, Fontes JOD, Janssens ACJW, Kronmal RA, Magnani JW, Witteman JC, Chamberlain AM, Lubitz SA, Schnabel RB, Agarwal SK, McManus DD, Ellinor PT, Larson MG, Burke GL, Launer LJ, Hofman A, Levy D, Gottdiener JS, Kääb S, Couper D, Harris TB, Soliman EZ, Stricker BHC, Gudnason V, Heckbert SR, Benjamin EJ. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. J Am Heart Assoc. 2013;2:e000102.
30. Rye K-A, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res. 2014;55:168-179.
31. Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2012;60:2263-2270.
32. Yang K-C, Dudley SC. Oxidative stress and atrial fibrillation: finding a missing piece to the puzzle. Circulation. 2013;128:1724-1726.
33. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, Aizawa Y. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008;117:1255-1260.
34. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010;159:850-856.
35. Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, Barzon I, Bishop L, Bonora E, Bunnag P, Chuang L-M, Deerochanawong C, Goldenberg R, Harshfield B, Hernández C, Herzlinger-Botein S, Itoh H, Jia W, Jiang Y-D, Kadowaki T, Laranjo N, Leiter L, Miwa T, Odawara M, Ohashi K, Ohno A, Pan C, Pan J, Pedro-Botet J, Reiner Z, Rotella CM, Simo R, Tanaka M, Tedeschi-Reiner E, Twum-Barima D, Zoppini G, Carey VJ. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation. 2014;129:999-1008.
36. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, Macfarlane PW; on behalf of the PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ. 2011;342:d1250.
37. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Hólm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart AFR, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett M-S, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki M-L, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PIW, Klungel OH, Maitland-van der Zee A-H, Peters BJM, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VHM, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WMM, Boer JMA, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordovas JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burtt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buysschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeir J, Schreiber S, Schäfer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardissino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altshuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380:572-580.
38. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [published online before print March 28, 2014]. Circulation. 2014. Available at: http://circ.ahajournals.org/content/early/2014/04/10/CIR.0000000000000041. Accessed August 28, 2014.